Ernexa Therapeutics Inc.: Form 10-K for the period ended Dec 31, 2012
Filed with the SEC on Mar 29, 2013 and accepted by EDGAR at Mar 29, 2013, 15:37 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-10-01 to 2012-12-31 | $5.9m | us-gaap:SalesRevenueNet |
| Revenue | 12 months2012-01-01 to 2012-12-31 | $24.1m | us-gaap:SalesRevenueNet |
| Selling, general and administrative | 12 months2012-01-01 to 2012-12-31 | $18.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2012-10-01 to 2012-12-31 | $479.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2012-01-01 to 2012-12-31 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2012-01-01 to 2012-12-31 | $44.0k | us-gaap:InterestExpense |
| Income tax | 12 months2012-01-01 to 2012-12-31 | −$83.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2012-10-01 to 2012-12-31 | $629.0k | us-gaap:NetIncomeLoss |
| Net income | 12 months2012-01-01 to 2012-12-31 | −$995.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2012-10-01 to 2012-12-31 | $0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2012-01-01 to 2012-12-31 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2012-01-01 to 2012-12-31 | $2.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2012-01-01 to 2012-12-31 | $1.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2012-12-31 | $2.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-12-31 | $4.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2012-12-31 | $12.7m | us-gaap:Assets |
| Current liabilities | At period end2012-12-31 | $3.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2012-12-31 | $4.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2012-12-31 | $7.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001019687-13-001065. Last ingested by Listed: Nov 6, 2026, 17:52 ET. Listed shows no prices and gives no investment advice.